News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
744,485 Results
Type
Article (53091)
Company Profile (645)
Press Release (690749)
Section
Business (214087)
Career Advice (3114)
Deals (37998)
Drug Delivery (125)
Drug Development (84603)
Employer Resources (184)
FDA (17118)
Job Trends (16533)
News (365200)
Policy (35932)
Tag
2024 BioCapital Digital (20)
2024 BioForest Digital (16)
2024 BioForest Standard (1)
2024 BioMidwest Digital (14)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (19)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (20)
2024 Biotech Beach Digital (15)
2024 Biotech Beach Standard (9)
2024 Genetown Digital (10)
2024 Genetown Standard (12)
2024 Lone Star Bio Digital (17)
2024 Pharm Country Digital (13)
2024 Pharm Country Standard (7)
2025 BioForest Digital (6)
2025 Lone Star Bio Digital (10)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (1)
Academia (2734)
Academic (2)
Accelerated approval (3)
Adcomms (27)
Allergies (85)
Alliances (52132)
ALS (91)
Alzheimer's disease (1436)
Antibody-drug conjugate (ADC) (136)
Approvals (17085)
Artificial intelligence (262)
Autoimmune disease (19)
Automation (14)
Bankruptcy (389)
Best Places to Work (12282)
BIOSECURE Act (21)
Biosimilars (114)
Biotechnology (440)
Bladder cancer (63)
Brain cancer (29)
Breast cancer (260)
Cancer (2086)
Cardiovascular disease (179)
Career advice (2619)
Career pathing (32)
CAR-T (160)
Cell therapy (434)
Cervical cancer (18)
Clinical research (68374)
Collaboration (823)
Compensation (456)
Complete response letters (30)
COVID-19 (2777)
CRISPR (41)
C-suite (222)
Cystic fibrosis (101)
Data (1958)
Decentralized trials (2)
Denatured (25)
Depression (48)
Diabetes (265)
Diagnostics (6787)
Digital health (19)
Diversity (7)
Diversity, equity & inclusion (43)
Drug discovery (119)
Drug pricing (119)
Drug shortages (33)
Duchenne muscular dystrophy (87)
Earnings (87050)
Editorial (39)
Employer branding (25)
Employer resources (157)
Events (119685)
Executive appointments (661)
FDA (18245)
Featured Employer (64)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (724)
Gene editing (105)
Generative AI (26)
Gene therapy (308)
GLP-1 (800)
Government (4629)
Grass and pollen (4)
Guidances (47)
Healthcare (19880)
Huntington's disease (24)
IgA nephropathy (25)
Immunology and inflammation (127)
Indications (27)
Infectious disease (2922)
Inflammatory bowel disease (145)
Inflation Reduction Act (9)
Influenza (51)
Intellectual property (86)
Interviews (605)
IPO (17517)
IRA (49)
Job creations (4753)
Job search strategy (2181)
Kidney cancer (9)
Labor market (34)
Layoffs (529)
Leadership (19)
Legal (9326)
Liver cancer (73)
Lung cancer (309)
Lymphoma (135)
Machine learning (2)
Management (63)
Manufacturing (299)
MASH (66)
Medical device (14268)
Medtech (14273)
Mergers & acquisitions (20952)
Metabolic disorders (707)
Multiple sclerosis (75)
NASH (23)
Neurodegenerative disease (96)
Neuropsychiatric disorders (31)
Neuroscience (1958)
NextGen: Class of 2025 (7233)
Non-profit (4612)
Northern California (2451)
Now hiring (38)
Obesity (387)
Opinion (268)
Ovarian cancer (74)
Pain (87)
Pancreatic cancer (79)
Parkinson's disease (140)
Partnered (21)
Patents (218)
Patient recruitment (96)
Peanut (51)
People (61431)
Pharmaceutical (133)
Pharmacy benefit managers (20)
Phase I (21168)
Phase II (30119)
Phase III (22742)
Pipeline (1023)
Podcasts (101)
Policy (132)
Postmarket research (2597)
Preclinical (8915)
Press Release (72)
Prostate cancer (96)
Psychedelics (38)
Radiopharmaceuticals (264)
Rare diseases (387)
Real estate (6786)
Recruiting (71)
Regulatory (24045)
Reports (44)
Research institute (2504)
Resumes & cover letters (474)
Rett syndrome (3)
RNA editing (3)
RSV (45)
Schizophrenia (74)
Series A (132)
Series B (83)
Service/supplier (27)
Sickle cell disease (54)
Southern California (2126)
Special edition (18)
Spinal muscular atrophy (159)
Sponsored (32)
Startups (4094)
State (2)
Stomach cancer (16)
Supply chain (65)
The Weekly (73)
United States (22057)
Vaccines (746)
Venture capitalists (39)
Webinars (12)
Weight loss (283)
Women's health (36)
Worklife (18)
Date
Today (112)
Last 7 days (627)
Last 30 days (2681)
Last 365 days (35756)
2025 (8250)
2024 (37493)
2023 (42168)
2022 (53462)
2021 (58069)
2020 (56533)
2019 (49417)
2018 (37550)
2017 (35492)
2016 (35307)
2015 (41030)
2014 (35646)
2013 (30534)
2012 (30632)
2011 (31075)
2010 (28765)
Location
Africa (962)
Alabama (56)
Alaska (7)
Arizona (197)
Arkansas (14)
Asia (45186)
Australia (7464)
California (5703)
Canada (1890)
China (499)
Colorado (255)
Connecticut (275)
Delaware (132)
Europe (99064)
Florida (813)
Georgia (202)
Hawaii (1)
Idaho (62)
Illinois (532)
India (27)
Indiana (311)
Iowa (10)
Japan (143)
Kansas (104)
Kentucky (25)
Louisiana (10)
Maine (68)
Maryland (844)
Massachusetts (4408)
Michigan (231)
Minnesota (386)
Mississippi (2)
Missouri (85)
Montana (31)
Nebraska (25)
Nevada (57)
New Hampshire (69)
New Jersey (1640)
New Mexico (31)
New York (1628)
North Carolina (1047)
North Dakota (8)
Northern California (2451)
Ohio (203)
Oklahoma (14)
Oregon (45)
Pennsylvania (1272)
Puerto Rico (10)
Rhode Island (29)
South America (1387)
South Carolina (19)
South Dakota (1)
Southern California (2126)
Tennessee (88)
Texas (855)
Utah (171)
Virginia (145)
Washington D.C. (65)
Washington State (549)
West Virginia (3)
Wisconsin (57)
744,485 Results for "la jolla pharmaceutical company".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
La Jolla Institute for Immunology and RevolKa started a Research Collaboration
RevolKa Ltd., a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology agreed to start a research collaboration to create antigens for the next-generation vaccines to deliver innovative solutions to unmet medical need in infectious diseases.
April 18, 2024
·
2 min read
Deals
Innoviva to Acquire La Jolla Pharmaceutical Company
Innoviva, Inc. and La Jolla Pharmaceutical Company announced that they have entered into a definitive merger agreement whereby Innoviva will acquire La Jolla.
July 11, 2022
·
10 min read
Deals
Innoviva Completes Acquisition of La Jolla Pharmaceutical
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of La Jolla Pharmaceutical Company (Nasdaq: LJPC) (“La Jolla”) at a price of $6.23 per share (the “Offer Price”).
August 22, 2022
·
5 min read
XNK presents at the 8th Innate Killer Summit in La Jolla, San Diego
XNK Therapeutics AB announced its extensive participation at the 8th Annual Innate Killer Summit in La Jolla, San Diego, CA, March 28-30.
March 22, 2023
·
2 min read
Press Releases
Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion
March 24, 2025
·
9 min read
Deals
Innoviva Snags Lucrative La Jolla Portfolio in $149M Deal
Innoviva Inc. and La Jolla Pharmaceutical Company announced Monday that they had entered into a $149-million merger agreement.
July 11, 2022
·
3 min read
·
Tristan Manalac
Business
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Corporate Progress
La Jolla Pharmaceutical Company announced financial results for the three months ended March 31, 2022 and highlighted corporate progress.
May 16, 2022
·
13 min read
Genetown
La Jolla Pharmaceutical, a Wholly Owned Subsidiary of Innoviva, Inc., Announces Data on XERAVA (eravacycline) to be Presented at IDWeek 2022
La Jolla Pharmaceutical Company today announced that five abstracts highlighting XERAVA (eravacycline) have been selected for poster presentation at IDWeek 2022, the annual meeting of the Infectious Disease Society of America taking place October 19-23, 2022 in Washington, D.C.
October 14, 2022
·
8 min read
Genetown
La Jolla Pharmaceutical Company Announces Share Repurchase Plan - Nov 17, 2021
La Jolla Pharmaceutical Company announced that it will commence a share repurchase plan for up to $10 million of the Company’s common stock.
November 17, 2021
·
1 min read
Business
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Corporate Progress
La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Corporate Progress.
March 9, 2022
·
15 min read
1 of 74,449
Next
